KR20140050412A - Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f2189 enhanced functionality of anti-diabetes and method of thereof - Google Patents
Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f2189 enhanced functionality of anti-diabetes and method of thereof Download PDFInfo
- Publication number
- KR20140050412A KR20140050412A KR1020120116799A KR20120116799A KR20140050412A KR 20140050412 A KR20140050412 A KR 20140050412A KR 1020120116799 A KR1020120116799 A KR 1020120116799A KR 20120116799 A KR20120116799 A KR 20120116799A KR 20140050412 A KR20140050412 A KR 20140050412A
- Authority
- KR
- South Korea
- Prior art keywords
- soybean
- strain
- fermented
- inoculated
- plantarum
- Prior art date
Links
- 244000068988 Glycine max Species 0.000 title claims abstract description 57
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 18
- 241000563903 Bacillus velezensis Species 0.000 title claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 title description 22
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract description 21
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 21
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 16
- 230000003178 anti-diabetic effect Effects 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 241000193744 Bacillus amyloliquefaciens Species 0.000 claims description 13
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 230000005764 inhibitory process Effects 0.000 abstract description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 244000063299 Bacillus subtilis Species 0.000 description 5
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000021107 fermented food Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 235000013555 soy sauce Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000001810 Angelica gigas Species 0.000 description 1
- 235000018865 Angelica gigas Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000000102 Bacillus subtilis subsp inaquosorum Nutrition 0.000 description 1
- 235000005744 Bacillus subtilis subsp subtilis Nutrition 0.000 description 1
- 241000220915 Bacillus subtilis subsp. inaquosorum Species 0.000 description 1
- 241000948854 Bacillus subtilis subsp. subtilis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000842368 Homo sapiens Protein HIRA Proteins 0.000 description 1
- 235000008586 Hovenia Nutrition 0.000 description 1
- 241000405398 Hovenia Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 102100030473 Protein HIRA Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 108010083364 chungkookjang Proteins 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 항당뇨 효과가 증강된 콩발효물 및 이의 제조방법에 관한 것이다.The present invention relates to a soybean fermented product having enhanced antidiabetic effect and a process for producing the same.
경제발전이 가속화되고 식생활 문화가 점점 서구화 및 간편화되면서, 이와 관련한 대사성 증후군 발병률이 점차 증가하고 있는데, 대표적인 질환 중 하나가 당뇨병이다. 대한당뇨병학회와 심평원에서 실시한 한국인 당뇨병 역학조사 결과에 따르면 2005년 국내 당뇨병으로 고통받는 환자는 270만명(전체 인구의 7.7%)이며, 2020년에는 455만명(전체 인구의 8.97%), 2030년에는 545만명(전체 인구의 10.85%) 에 이를 것으로 추정되고 있다. 또한 매년 전체 환자의 10%에 달하는 신규환자가 발생하는 등 당뇨병에 대한 국가차원의 예방관리 시스템이 필요한 실정이다. 당뇨병은 발병 원인에 따라 제 1형 당뇨와 제 2형 당뇨로 구분되는데, 전체 당뇨병의 90%에 해당하는 제 2형 당뇨병은 근육, 간, 지방조직에서 다양한 요인에 의해 인슐린 작용이 저하되어 췌장의 베타세포가 인슐린 저항성을 극복할 수 있을 만큼 인슐린을 분비하지 못하여 혈중 포도당 농도가 높게 지속될 때 유발된다. 당뇨병에 걸리게 되면 당의 이용률이 낮아지고 소변으로 당을 잃게 되기 때문에 에너지원으로 사용되어야 할 당을 세포가 이용하지 못하여 충분한 에너지를 생산할 수 없게 되며, 결국 체내의 단백질을 에너지원으로 사용하게 되면서 피로를 느끼고 체중이 감소하게 된다. 또한 신장 기능의 저하, 동맥경화, 망막 출혈로 인한 시력 저하, 족부 궤양, 말초신경병증 등 다양한 합병증을 유발하게 되는데, 2007년 당뇨병 합병증인 말초순환장애 및 당뇨병성 망막증 환자의 경우 전년 대비 각각 60% 및 36% 가량 증가한 것으로 나타났다. 이처럼 당뇨병은 그 자체의 발병률이 점차 증가하고 있을 뿐만 아니라, 수반되는 합병증 발병률이 높다는 특성을 가지고 있어 의료비용(건강보험 총진료비의 5분의 1이 당뇨병 환자 총진료비) 및 인력손실 등 막대한 사회적 손실이 발생되고 있다. 그럼에도 불구하고 아직까지 당뇨병을 근원적으로 치료할 수 있는 약물을 개발하지 못하고 있는 실정이다.As economic development accelerates and the food culture becomes more westernized and simplified, the incidence of metabolic syndrome related to this is gradually increasing. One of the representative diseases is diabetes. According to the Korean Diabetes Epidemiology Survey conducted by the Korean Diabetes Association and the HIRA, 2.7 million people (7.7% of the total population) suffered from domestic diabetes in 2005, 4.55 million (8.97% of the total population) by 2020, It is estimated to reach 5.45 million (10.85% of the total population). In addition, a nationwide preventive management system for diabetes is required, including 10% of new patients every year. Diabetes mellitus is divided into type 1 diabetes and type 2 diabetes according to the etiology of the disease. Type 2 diabetes, which accounts for 90% of all diabetes, is caused by insulin action due to various factors in muscle, liver, It is caused when the beta cells do not secrete insulin enough to overcome insulin resistance and the blood glucose concentration continues to be high. If diabetes occurs, the sugar utilization rate is lowered and the sugar is lost in the urine. As a result, the sugar can not be used as an energy source and thus the energy can not be produced. As a result, the protein in the body is used as an energy source, Feel and lose weight. In addition, patients with diabetic retinopathy and diabetic retinopathy, which are complications of diabetes in 2007, will experience 60% or more of a year-on-year increase in complications, such as decreased renal function, arteriosclerosis, decreased visual acuity due to retinal hemorrhage, And 36%, respectively. As such, the incidence of diabetes itself is increasing, and the accompanying complication rate is high. Therefore, the cost of medical care (one-fifth of total health care costs for diabetes patients) . Nevertheless, it is not yet possible to develop a drug that can cure diabetes.
상기의 당뇨병을 예방 또는 치료하는 방법으로 인슐린이나 경구 혈당 강하제의 투여가 이루어지고 있는데, 경제적 부담과 더불어 부작용의 위험도 수반하고 있기 때문에 근래에 와서는 천연식물 등의 약리물질을 이용한 식이 요법 및 자연 요법이 시도되고 있다. 당뇨병 치료에 효과가 있다고 보고된 천연물로서는 뜸부기 추출물(대한민국 특허 제464815호), 잔나비걸상버섯으로부터 분리한 아플아나산 유도체 화합물(대한민국 특허 제457690호), 헛개나무의 추출물(대한민국 특허 제417287호), 참당귀에서 분리한 다당류(국제공개 제2001-60386호), 반추동물의 담즙(미국특허 제6451355호) 등을 예시할 수 있다.
Since insulin or oral hypoglycemic agent is administered to prevent or treat the above-mentioned diabetes, since it is accompanied by an economic burden and a risk of side effects, recently, dietary and natural therapies using pharmacological substances such as natural plants This is being attempted. As the natural products reported to be effective for the treatment of diabetes, there have been reported the extracts of Cucurbitaceae (Korean Patent No. 464815), the phthalic acid derivatives (Korean Patent No. 457690) and the extracts of Hovenia dulcifera (Korean Patent No. 417287) , Polysaccharides isolated from Angelica gigas Nakai (International Publication No. 2001-60386), and ruminant bile (US Patent No. 6451355).
한편, 청국장은 대두에 고초균을 이용하여 2-3일간의 짧은 발효를 통해 제조하는 한국의 대표적인 발효식품으로 면역증진, 항암 활성을 가지며 당뇨나 고지혈증과 같은 대사성 질환 예방 및 억제에 효과가 있다고 알려져 있다. 그러나 청국장의 이런 다양한 생리활성들은 제조 시 사용하는 종균의 종류에 따라 활성의 차이가 나타나므로 생리활성을 높은 청국장을 제조하기 위해서는 기능성이 뛰어난 종균을 이용하여 발효를 진행하여야 한다.
On the other hand, Chungkookjang is Korea's representative fermented food produced by short fermentation for 2-3 days using Bacillus subtilis in soybean, and it is known that it has immunity enhancement, anticancer activity and is effective for prevention and inhibition of metabolic diseases such as diabetes and hyperlipidemia . However, since these various physiological activities of chongkukjang exhibit different activities depending on the kinds of seeds used in production, fermentation should be carried out using seeds having excellent functionality in order to produce chungkukjang having high physiological activity.
이에 본 발명자는 전통발효식품으로부터 높은 알파글루코시다아제 저해 활성을 가지는 균주를 분리하고 이를 균주를 이용하여 알파글루코시다아제 저해 작용을 통해 식후 혈당 조절에 탁월한 효과를 보이는 콩발효물을 제조하여 본 발명을 완성하였다.Thus, the present inventors isolated a strain having high alpha glucosidase inhibitory activity from a conventional fermented food, and produced a soybean fermented product exhibiting an excellent effect on postprandial blood glucose control through the inhibition of alpha glucosidase using the strain, .
이와 같이, 본 발명은 높은 알파글루코시다아제 저해 활성을 가지는 균주를 전통발효식품으로부터 분리하고 이를 이용하여 콩발효물을 제조하는 방법을 제공하는 것을 목적으로 한다.Thus, it is an object of the present invention to provide a method of isolating a strain having high alpha glucosidase inhibitory activity from a conventional fermented food and using the fermented soybean fermented product to produce a soybean fermented product.
상기 목적을 달성하기 위하여 본 발명의 일 구체예에서 알파글루코시다제 저해활성을 가지는 것을 특징으로 하는 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)을 제공한다.
In order to accomplish the above object, in one embodiment of the present invention, Bacillus amyloliquefaciens subsp. Sp. F2189 ( Bacillus sp.) Having an alpha glucosidase inhibitory activity amyloliquefaciens subsp . Plantarum F2189, KCCM11282P).
본 발명의 다른 구체예에서 바실러스속 균주를 증자시킨 대두에 접종하는 단계; 및 상기 균주를 접종시킨 대두를 발효시키는 단계를 포함하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법을 제공한다.In another embodiment of the present invention, the step of inoculating soybeans with a strain of Bacillus subtilis grown; And fermenting soybeans inoculated with the strain. The present invention also provides a method for producing soybean fermented product having enhanced antidiabetic effect.
본 발명에 있어서, 상기 균주는 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)일 수 있고, 상기 균주는 증자시킨 대두량의 0.05 내지 5 중량%를 접종할 수 있으며, 상기 균주를 접종시킨 대두는 습도 60 내지 80%의 조건에서 발효될 수 있으며, 상기 균주를 접종시킨 대두는 30 내지 45℃의 온도에서 발효될 수 있으며, 상기 균주를 접종시킨 대두는 1 내지 5일간 발효시킬 수 있다.
In the present invention, the strain is Bacillus amyl Lowry query Pacific Enschede sub Spanish cis Planta columns F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, and KCCM11282P). The strain may be inoculated in an amount of 0.05 to 5% by weight based on the amount of soybeans added. The soybean inoculated with the strain may be fermented under conditions of 60 to 80% relative humidity. The inoculated soybean can be fermented at a temperature of 30 to 45 ° C, and the soybean inoculated with the strain can be fermented for 1 to 5 days.
본 발명의 또 다른 구체예에서 상기의 방법에 따라 제조된 항당뇨 효과가 증진된 콩 발효물을 유효성분으로 포함하는 식품을 제공한다.
In another embodiment of the present invention, there is provided a food comprising the fermented soybean having an improved antidiabetic effect according to the above method as an active ingredient.
본 발명의 또 다른 구체예에서 바실러스속 균주 및 증자시킨 대두를 포함하는 항당뇨 효과가 증진된 콩 발효물을 제공한다.In another embodiment of the present invention, there is provided a soybean fermentation product enhanced in an antidiabetic effect comprising a strain of Bacillus subtilis and a soybean grown therein.
본 발명에 있어서, 상기 균주는 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)일 수 있고, 상기 균주는 증자시킨 대두량의 0.05 내지 5 중량%일 수 있으며, 상기 균주를 접종시킨 대두는 습도 60 내지 80%의 조건에서 발효된 것일 수 있으며, 상기 균주를 접종시킨 대두는 30 내지 45℃의 온도에서 발효된 것일 수 있으며, 상기 균주를 접종시킨 대두는 1 내지 5일간 발효된 것일 수 있다.
In the present invention, the strain is Bacillus amyl Lowry query Pacific Enschede sub Spanish cis Planta columns F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P), and the strain may be 0.05 to 5% by weight of the amount of soybean added, and the soybean inoculated with the strain may be fermented under the conditions of 60 to 80% of humidity, The soybean may be fermented at a temperature of 30 to 45 ° C, and the soybean inoculated with the strain may be fermented for 1 to 5 days.
본 명세서에서 사용하는 "콩발효물"은 콩을 원료로 하는 미생물의 발효 작용을 이용하여 제조한 것을 의미하며, 콩발효물의 일 예로, 이에 제한되는 것은 아니나, 된장, 고추장, 메주, 청국장 및 간장이 포함된다.
As used herein, the term "soybean fermented product" means a soybean fermented product produced by utilizing the fermentation action of microorganisms using soybean as a raw material. Examples of soybean fermented products include, but are not limited to, miso, kochujang, meju, .
본 발명에서 당뇨병은 인슐린 분비 혹은 인슐린의 세포에 대한 작용이 저하되어 체내로 들어온 당의 흡수가 정상적으로 일어나지 않는 질병으로 고혈당을 수반하는데, 탄수화물 대사뿐만 아니라 지질 및 단백질 대사의 이상을 초래하여 고인슐린증, 죽상경화, 망막출혈, 고혈압 등과 같은 다양한 합병증을 유발하게 된다. 당뇨병 치료방법으로 식이요법, 운동요법과 함께 약물요법이 병용되고 있는데, 임상에서 많이 이용되는 약물은 인슐린 제제, 설폰요소제 제제, 바이구아니드 제제, 트로글리타존 제제, 알파글루코시다아제 저해제 등이 있다. 이 중 알파글루코시다아제 저해제는 음식물 중의 소당류와 이당류의 분해 속도를 감소시켜 식후 혈당의 급속한 상승과 그에 따른 혈액 내의 인슐린 반응을 감소시키기 때문에 당뇨병 예방 및 치료에 이용되고 있는데, 아카보스와 보글리보스등이 대표적인 알파글루코시다아제 저해제이다.
In the present invention, diabetes mellitus is a disease in which insulin secretion or action of insulin on cells is decreased and absorption of glucose into the body does not normally occur. It involves hyperglycemia. It causes not only carbohydrate metabolism but also lipid and protein metabolism, Atherosclerosis, retinal hemorrhage, hypertension, and the like. Diabetes therapy and exercise therapy as well as pharmacotherapy are used in diabetes therapy. Drugs commonly used in clinical practice are insulin preparations, sulphonylurea preparations, biguanide preparations, troglitazone preparations, and alpha glucosidase inhibitors. Among them, the alpha glucosidase inhibitor is used for the prevention and treatment of diabetes because it decreases the decomposition rate of the small saccharides and disaccharides in the food to reduce the postprandial increase in blood glucose and the insulin reaction in the blood, This is an exemplary alpha glucosidase inhibitor.
본 발명에서 '청국장'은 콩을 불리고 찐 다음, 고온(40℃)에서 발효하여 바실러스(Bacillus)속 균이 증식하면서 끈끈한 점성물질이 생긴 발효식품을 말한다. 상기 청국장에는 바실러스 속 세균이 주요 미생물로 함유되어 있다.In the present invention, 'Chungkukjang' refers to a fermented food in which soybean is fermented at a high temperature (40 ° C) after being called and steamed, and a bacterium belonging to the genus Bacillus is propagated to produce a sticky viscous substance. The Chungkukjang contains Bacillus spp. As a major microorganism.
상술한 바와 같이 본 발명에서는 높은 알파글루코시다아제 저해 활성을 가지는 균주로 인해 항당뇨 활성을 가지는 콩발효물을 제공한다.As described above, the present invention provides a fermented soybean having antidiabetic activity due to a strain having high alpha glucosidase inhibitory activity.
이하 본 발명의 내용을 실시예 및 시험예를 통해 더욱 상세하게 설명하기로 한다. 다만, 이들 실시예 본 발명의 내용을 이해하기 위해 제시되는 것일 뿐 본 발명의 권리범위가 이들 실시예로 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. It is to be understood, however, that the scope of the present invention is not limited to these embodiments.
실시예Example
실시예Example 1. 균주 분리 및 동정 1. Isolation and Identification of Strain
균주는 트립티케이스 대두 한천(Difco, USA) 배지를 이용하여 재래식으로 제조된 간장으로부터 분리하였으며, 16S rDNA 시퀀싱을 통해 균주를 동정하였다. 동정 결과, 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)은 종래 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼(Bacillus amyloliquefaciens subsp . Plantarum)과 100%의 높은 상동성을 보였으며, 본 발명에 사용한 균주는 2012년 6월 14일자로 KCCM에 기탁하였다.
The strains were isolated from conventional soy sauce broth using trypticase soybean agar (Difco, USA) and identified by 16S rDNA sequencing. As a result of identification, Bacillus amyloliquefaciens subsp . Plantarum F2189 ( Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P) is a conventional Bacillus amyl Lori query Pacifico Enschede sub-Made Systems Planta Rum (Bacillus amyloliquefaciens subsp . Plantarum ), and the strain used in the present invention was deposited with KCCM on June 14,
실시예Example 2. 청국장의 제조 2. Manufacture of Chungkukjang
청국장 제조를 위해 대두를 세척 후 하룻밤 동안 침지한 후 물기를 제거하고 114℃에서 50 분간 증자하였다. 증자한 후 식힌 대두 200g에 균주를 대두량의 1%가 되도록 접종하고 습도 70%, 온도 37℃ 항온기에서 3일간 발효시켜 청국장을 제조하였다. 이를 동결 건조한 후 분쇄하여 -20℃에서 보관하며 알파글루코시다아제 저해활성을 측정하였다.
The soybean was washed for the preparation of Chongkukjang, and the soybean was soaked overnight, then the water was removed and the soybean was heated at 114 ° C for 50 minutes. After the addition, the strain was inoculated to 200 g of chilled soybeans so that the strain became 1% of the soybean yield and fermented in a thermostat at a temperature of 37 ° C and a humidity of 70% for 3 days to prepare chungkukjang. It was freeze-dried, pulverized, stored at -20 ° C, and the activity of alpha glucosidase inhibition was measured.
실시예Example 3. 3. 알파글루코시다아제의Alpha-glucosidase 저해활성 측정 Measurement of inhibitory activity
상기 실시예 2에 따라 제조된 청국장 10g에 증류수를 10 배량 가한 후 200 rpm으로 60분간 혼합하며 추출하였다. 이를 10분간 가열하고 10,000 rpm에서 10 분간 원심 분리한 후 상층액의 알파글루코시다아제 저해활성을 측정하였다. 96 웰 플레이트에 상층액 147 uL, 30 uL 0.1 M 인산완충액(pH 7.2), 30 uL PNPG (1.42 mM) 및 5 uL 알파글루코시다아제(1.8 U/ml)을 첨가한 후 37℃에서 10 분간 반응 시켰다. 10 분 후 0.5 M Na2CO3을 100 uL 가하여 반응을 중지시키고 405nm에서 흡광도를 측정하였다. 저해율은 아래 식을 통해 산출하였다.10 g of the chungkukjang prepared according to Example 2 was added with 10 times of distilled water, followed by mixing at 200 rpm for 60 minutes. After heating for 10 minutes and centrifuging at 10,000 rpm for 10 minutes, the activity of alpha glucosidase inhibition of the supernatant was measured. To the 96 well plate was added 147 μL of the supernatant, 30 μL of 0.1 M phosphate buffer (pH 7.2), 30 μL of PNPG (1.42 mM) and 5 μL of alpha glucosidase (1.8 U / mL) . After 10 minutes, the reaction was stopped by adding 100 uL of 0.5 M Na 2 CO 3 and absorbance was measured at 405 nm. The inhibition rate was calculated by the following equation.
저해율(%) = [1-(A405 of sample-A405 of blank)/A405 of control]×100 Inhibition rate (%) = [1- (A 405 of sample-A 405 of blank) / A 405 of control] × 100
0
0
시판청국장1, 2, 3, 4와 균주를 접종하지 않은 증자한 대두에서는 알파 글루코시다아제 저해활성이 거의 없는 반면, 간장에서 분리한 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)으로 제조한 청국장은 55.6%의 높은 알파 글루코시다아제 저해율을 보였다. 간장, 메주, 젓갈등의 전통발효식품에서 분리한 다른 균주인 바실러스 서브틸리스 서브스페시스 서브틸리스 210(Bacillus subtilis subsp . subtilis 210), 바실러스 리케니포미스 248( Bacillus lichenifomis 248), 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 21(Bacillus amyloliquefaciens subsp . plantrum 21), 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 471(Bacillus amyloliquefaciens subsp . plantrum 471) 및 바실러스 서브틸리스 서브스페시스 인아쿠오소룸 387 (Bacillus subtilis subsp . inaquosorum 387) 등을 이용하여 제조한 청국장에서는 알파글루코시다아제 저해활성이 낮게 검출된 것으로 미루어 보아 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)을 이용하여 제조한 청국장에서 알파글루코시다아제 저해 활성이 현저히 높아짐을 확인할 수 있었다.
Bacillus amyloliquefaciens subspecies F2189 ( Bacillus spp.) Isolated from soy sauce was found to have little inhibitory activity against commercially available chungkukjang 1, 2, 3, 4 and soybean without added strain, amyloliquefaciens subsp . Plantarum F2189, KCCM11282P) showed a high inhibition rate of alpha glucosidase of 55.6%. Bacillus subtilis subspecies 210 ( Bacillus sp.) , Another strain isolated from traditional fermented foods such as soy sauce, meju, subtilis subsp . subtilis 210), Bacillus Lee Kenny Po Ms 248 (Bacillus lichenifomis 248) , Bacillus amyloliquefaciens subsp. Plantarum 21 ( Bacillus amyloliquefaciens subsp . plantrum 21), Bacillus amyloliquefaciens subsp . Plantrum ( Bacillus amyloliquefaciens subsp . 471) And Bacillus subtilis subspecies inactivosum 387 ( Bacillus < RTI ID = 0.0 > subtilis subsp . inaquosorum 387), it was found that Bacillus amyloliquefaciens subsp . Plantarum F2189 ( Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P), the activity of inhibiting alpha glucosidase was significantly increased.
또한, 균주배양액 자체의 알파글루코시다아제 저해 활성을 측정해본 결과 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp. Plantarum F2189, KCCM11282P) 배양액 자체에서 알파글루코시다아제 저해 활성이 36.35%임을 확인함으로써, 균주 자체가 알파글루코시다아제 저해 활성을 가지고 있으며, 이것을 청국장으로 제조함으로 인해 그 활성이 더 높아지는 것을 확인하였다.
In addition, the results done measuring the alpha-glucosidase inhibitory activity of the Bacillus strain culture solution itself amyl Lowry query Pacific Enschede sub Spanish cis Planta columns F2189 (Bacillus amyloliquefaciens subsp. Plantarum F2189 and KCCM11282P), the activity of alpha-glucosidase inhibition activity was 36.35%, confirming that the strain itself had alpha-glucosidase inhibitory activity and that its activity was further enhanced by preparing it with chungkukjang.
소장융막부분의 알파글루코시다아제는 알파아밀라아제에 의해 분해된 당질을 최종적으로 단당류로 전화시키므로 식후 혈당 상승을 억제 할 수 있다. 따라서 알파 글루코시다아제 저해활성을 가지는 물질은 당뇨병의 예방 및 치료에 이용될 수 있다. 따라서, 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P) 및 이 균주로 제조한 청국장은 알파글루코시다아제 저해활성이 높아 탄수화물의 소화과정에서 단당류 생성을 효과적으로 저해할 수 있으므로 식후 혈당 조절을 통한 당뇨 예방 및 치료에 이용할 수 있을 것으로 판단된다.
Alpha glucosidase in the small intestinal mucosa is able to inhibit postprandial hyperglycemia because the saccharides degraded by alpha amylase are finally converted into monosaccharides. Therefore, a substance having an alpha glucosidase inhibitory activity can be used for prevention and treatment of diabetes. Thus, Bacillus amyloliquefaciens F2189 ( Bacillus amyloliquefaciens < RTI ID = 0.0 > subsp . Plantarum F2189, KCCM11282P) and chungkukjang prepared with this strain have high alpha-glucosidase inhibitory activity and can effectively inhibit the formation of monosaccharides in the digestion process of carbohydrates, so that it can be used for prevention and treatment of diabetes through postprandial glucose control.
지금까지 예시적인 실시 태양을 참조하여 본 발명을 기술하여 왔지만, 본 발명의 속하는 기술 분야의 당업자는 본 발명의 범주를 벗어나지 않고서도 다양한 변화를 실시할 수 있으며 그의 요소들을 등가물로 대체할 수 있음을 알 수 있을 것이다. 또한, 본 발명의 본질적인 범주를 벗어나지 않고서도 많은 변형을 실시하여 특정 상황 및 재료를 본 발명의 교시내용에 채용할 수 있다. 따라서, 본 발명이 본 발명을 실시하는데 계획된 최상의 양식으로서 개시된 특정 실시 태양으로 국한되는 것이 아니며, 본 발명이 첨부된 특허청구의 범위에 속하는 모든 실시 태양을 포함하는 것으로 해석되어야 한다.While the present invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. You will know. In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Accordingly, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention be construed as including all embodiments falling within the scope of the appended claims.
Claims (14)
상기 균주를 접종시킨 대두를 발효시키는 단계를 포함하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법.Inoculating Bacillus strains with increased soybean; And
And fermenting the soybeans inoculated with the strain to produce soybean fermented product having enhanced antidiabetic effect.
상기 균주는 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)인 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법.3. The method of claim 2,
This strain is Bacillus amyl Lowry query Pacific Enschede sub Spanish cis Planta columns F2189 (Bacillus amyloliquefaciens subsp. Plantarum F2189, KCCM11282P) method for producing a fermented soybean with enhanced anti-diabetic effect, characterized in that.
상기 균주는 증자시킨 대두량의 0.05 내지 5 중량%를 접종하는 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법.3. The method of claim 2,
The strain is inoculated with 0.05 to 5% by weight of the amount of soybeans to increase the method for producing soybean fermented products with enhanced anti-diabetic effect.
상기 균주를 접종시킨 대두는 습도 60 내지 80%의 조건에서 발효되는 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법.3. The method of claim 2,
Wherein the soybean inoculated with the strain is fermented under a condition of a humidity of 60 to 80%.
상기 균주를 접종시킨 대두는 30 내지 45℃의 온도에서 발효되는 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법.3. The method of claim 2,
Wherein the soybean inoculated with the strain is fermented at a temperature of 30 to 45 캜.
상기 균주를 접종시킨 대두는 1 내지 5일간 발효시키는 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물을 제조하는 방법.3. The method of claim 2,
Wherein the soybean inoculated with the strain is fermented for 1 to 5 days.
상기 균주는 바실러스 아밀로리쿼파시엔스 서브스페시스 플란타럼 F2189 (Bacillus amyloliquefaciens subsp . Plantarum F2189, KCCM11282P)인 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물.The method of claim 8,
This strain is Bacillus amyl Lowry query Pacific Enschede sub Spanish cis Planta columns F2189 (Bacillus amyloliquefaciens subsp. Plantarum F2189, KCCM11282P) soybean fermented product with enhanced anti-diabetic effect.
상기 균주는 증자시킨 대두량의 0.05 내지 5중량%인 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물.The method of claim 8,
Wherein the strain is 0.05 to 5% by weight of the amount of soybeans added.
상기 균주를 접종시킨 대두는 습도 60 내지 80%의 조건에서 발효된 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물.The method of claim 8,
Wherein the soybean inoculated with the strain is fermented under a condition of a humidity of 60 to 80%.
상기 균주를 접종시킨 대두는 30 내지 45℃의 온도에서 발효된 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물.The method of claim 8,
Wherein the soybean inoculated with the strain is fermented at a temperature of 30 to 45 占 폚.
상기 균주를 접종시킨 대두는 1 내지 5일간 발효된 것을 특징으로 하는 항당뇨 효과가 증진된 콩 발효물. The method of claim 8,
Wherein the soybean inoculated with the strain is fermented for 1 to 5 days.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120116799A KR101437649B1 (en) | 2012-10-19 | 2012-10-19 | Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f2189 enhanced functionality of anti-diabetes and method of thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120116799A KR101437649B1 (en) | 2012-10-19 | 2012-10-19 | Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f2189 enhanced functionality of anti-diabetes and method of thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20140050412A true KR20140050412A (en) | 2014-04-29 |
KR101437649B1 KR101437649B1 (en) | 2014-09-05 |
Family
ID=50655590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120116799A KR101437649B1 (en) | 2012-10-19 | 2012-10-19 | Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f2189 enhanced functionality of anti-diabetes and method of thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101437649B1 (en) |
-
2012
- 2012-10-19 KR KR1020120116799A patent/KR101437649B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR101437649B1 (en) | 2014-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101825836B1 (en) | Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of diabetes or insulin resistance syndrome containing the same | |
KR20230005057A (en) | Anti-aging composition using combination therapy comprising Lactobacilli us sp. and oriental medicine | |
KR101422078B1 (en) | Manufacturing method of fermented Ophipogon japonicus for improving of blood flow using Cordyceps militaris and Lactic acid bacteria | |
KR20150074518A (en) | Compositon for preventing and treating diabetes and hypertension comprising fermented broth of plant-originated Lactic acid bacteria | |
KR101515839B1 (en) | Fermentative bitter melon juice and method of preparing the same | |
KR100773059B1 (en) | Novel microorganism having deglycosylating ability, the probiotics containing the same and the process for preparing them | |
JP5421348B2 (en) | Pharmaceutical composition for prevention and treatment of diabetes containing as an active ingredient an extract of chrysanthemum fermented with Lactobacillus microorganisms | |
KR101688090B1 (en) | Composition for anti-diabetes with the extract of Helianthus tuberosus, rice bran, Schizandra chinensis, Momordica charantin | |
KR101412210B1 (en) | Fermented soybean containing bacillus subtilis subsp. inaquosorum fa 0718 enhanced functionality of anti-diabetes and method of thereof | |
Ju et al. | Hypoglycemic effect of fermented soymilk added with bokbunja (Rubus coreanus Miquel) in diabetic mice | |
Yang et al. | The effect of natural soluble polysaccharides on the type 2 diabetes through modulating gut microbiota: A review | |
KR101437648B1 (en) | Fermented soybean containing bacillus arybhattai f1253 enhanced functionality of anti-diabetes and method of thereof | |
KR101270599B1 (en) | Fermented red ginseng composition containing fermented red ginseng and medical plant extracts exhibiting antidiabetic activity | |
KR101466869B1 (en) | Fermented soybean containing bacillus methylotrophicus tpp 0025 enhanced functionality of anti-diabetes and method of thereof | |
KR101669580B1 (en) | - Bacillus amyloliquefaciens strain having protease activity and -glucosidase inhibition activity and uses thereof | |
KR101437649B1 (en) | Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f2189 enhanced functionality of anti-diabetes and method of thereof | |
KR101462509B1 (en) | Fermented soybean containing bacillus amyloliquefaciens subsp. plantarum f1275 enhanced functionality of anti-diabetes and method of thereof | |
KR102668947B1 (en) | Composition for improving preventing or treating muscular disease including Lactobacillus plantarum Q1(LPQ1) | |
KR101412213B1 (en) | Fermented soybean containing bacillus subtilis subsp. inaquosorum fa 0305 enhanced functionality of anti-diabetes and method of thereof | |
KR20230153832A (en) | Composition for lowering blood glucose comprising Limosilactobacillus fermentum MG4295 | |
KR101722584B1 (en) | Butchu fermentated extract using Lactic acid bacteria sp. and anti-diabetic composition comprising the same | |
CN114223892A (en) | Microecological extract with function of reducing uric acid and preparation method thereof | |
KR20210066246A (en) | Manufacturing method of rice syrup comprising Muscat Bailey A | |
KR102689442B1 (en) | Edible insect fermentation products fermented using probiotic strain and uses thereof | |
KR20200124107A (en) | Composition comprising fermented extract of Perilla frutescens for preventing, improving or treating retinal diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170908 Year of fee payment: 4 |